ArticleNature communications2026
Site-specific protein functionalization by late-stage reversible cysteine masking.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Site-selective functionalization strategies are essential for generating complex proteins for basic research and biomedical applications. However, achieving precise transformations across protein sequences remains a significant challenge and often requires protein engineering with orthogonal handles or sequence interventions to achieve selectivity. Here, we report a modular strategy for site-selective protein functionalization that enables the selective targeting of desired Cys residues through late-stage reversible thiol caging. This strategy involves splitting the protein sequence into two segments and transiently masking native Cys residues to enable chemoselective ligation, thereby restoring the full-length protein with a single reactive Cys for late-stage functionalization. A subsequent decaging step regenerates the native Cys residues, yielding the desired site-specifically modified protein while preserving the native sequence. We demonstrate the versatility of this strategy through multiple transformations, including Cys arylation, alkylation, and elimination, and demonstrate the power of this approach by selective modification of 30 examples in high resolution. Furthermore, we apply this approach to edit Cys-rich zinc fingers, leading to the discovery of advanced analogs with enhanced DNA-binding activity. The versatility and modularity of the developed reversible thiol caging approach establish a powerful platform for site-selective protein modification, providing rapid access to structurally diverse proteins for fundamental research and therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.